<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The mechanisms that enable <z:hpo ids='HP_0002896'>liver cancer</z:hpo> to escape elimination by the immune system remain unclear, but their elucidation may provide novel therapeutic interventions </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the influence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-infiltrating regulatory T cells on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific T cell responses in patients with <z:hpo ids='HP_0002896'>liver cancer</z:hpo>, using ex vivo isolated cells from individuals with <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> (<z:mp ids='MP_0003331'>HCC</z:mp>) or <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (LM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Here we report that in both <z:mp ids='MP_0003331'>HCC</z:mp> and LM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, CD4+CD25+Foxp3+ regulatory T cells (Tregs) accumulate in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> milieu and are potent suppressors of autologous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific T cell responses </plain></SENT>
<SENT sid="3" pm="."><plain>Especially in LM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, where Treg accumulation is more prominent, there is good evidence for local proliferation of Tregs at the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> site </plain></SENT>
<SENT sid="4" pm="."><plain>We show that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> Tregs up-regulate the expression of <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi>-induced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor receptor (GITR) compared with Tregs in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-free liver tissue and blood </plain></SENT>
<SENT sid="5" pm="."><plain>Importantly, treatment with soluble GITR ligand (GITRL) induces a decrease in the suppression mediated by the activated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-infiltrating Tregs and restores the proliferative capacity and cytokine production of CD4+CD25- T cells </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Our results show that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated Tregs are critical for immune evasion in <z:hpo ids='HP_0002896'>liver cancer</z:hpo>, and we propose that GITRL constitutes a rational treatment for this disease </plain></SENT>
</text></document>